Payment overview · 2025
General Payments
$1,291.24
64 reported records · 15 companies
Healthcare provider profile · identity verified
Adam M Carpentieri, DO
Allopathic & Osteopathic Physicians|Family Medicine|Adult Medicine · MASSAPEQUA, NY · NPI 1275617193
Verified facts
What the public records show
CMS Open Payments records show Adam M Carpentieri, DO received $1,291.24 in general payments during 2025 across 64 reported records.
ABBVIE INC. accounted for 24.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Ozempic, Rexulti, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 409 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $319.29 | 24.7% | 21 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $171.63 | 13.3% | 12 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $147.91 | 11.4% | 11 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $144.84 | 11.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$123.38 | 9.6% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $108.04 | 8.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.11 | 4.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.79 | 4.0% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $42.54 | 3.3% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $31.86 | 2.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.79 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.81 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.11 | 1.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.65 | 1.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.49 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,291.24 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $217.37 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $199.70 | 13 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $171.63 | 12 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $144.84 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $144.84 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $144.84 | 1 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $123.38 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $108.04 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.21 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $64.21 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $56.11 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $42.54 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $31.86 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.81 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.65 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 72 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
72 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 18 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 15 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
56 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
409 | 67 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 999 | 178 |
| Atorvastatin Calcium | Atorvastatin Calcium | 960 | 200 |
| Amlodipine Besylate | Amlodipine Besylate | 724 | 159 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 642 | 148 |
| Furosemide | Furosemide | 549 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 500 | 99 |
| Losartan Potassium | Losartan Potassium | 466 | 103 |
| Eliquis | Apixaban | 409 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 384 | 71 |
| Potassium Chloride | Potassium Chloride | 361 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 344 | 66 |
| Gabapentin | Gabapentin | 320 | 64 |
| Simvastatin | Simvastatin | 318 | 58 |
| Donepezil Hcl | Donepezil Hcl | 315 | 49 |
| Sertraline Hcl | Sertraline Hcl | 315 | 57 |
| Famotidine | Famotidine | 313 | 68 |
| Omeprazole | Omeprazole | 287 | 63 |
| Metformin Hcl | Metformin Hcl | 254 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 253 | 50 |
| Metoprolol Tartrate | Metoprolol Tartrate | 234 | 50 |
| Lisinopril | Lisinopril | 230 | 47 |
| Trazodone Hcl | Trazodone Hcl | 220 | 46 |
| Mirtazapine | Mirtazapine | 219 | 35 |
| Meloxicam | Meloxicam | 201 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 189 | 45 |
| Carvedilol | Carvedilol | 173 | 37 |
| Memantine Hcl | Memantine Hcl | 165 | 30 |
| Montelukast Sodium | Montelukast Sodium | 162 | 39 |
| Quetiapine Fumarate | Quetiapine Fumarate | 159 | 30 |
| Finasteride | Finasteride | 125 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 125 | 56 |
| Celecoxib | Celecoxib | 121 | 31 |
| Torsemide | Torsemide | 111 | 19 |
| Allopurinol | Allopurinol | 109 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 97 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 95 | 30 |
| Ezetimibe | Ezetimibe | 89 | 21 |
| Farxiga | Dapagliflozin Propanediol | 89 | 22 |
| Xarelto | Rivaroxaban | 88 | 15 |
| Divalproex Sodium | Divalproex Sodium | 85 | 16 |
| Alprazolam | Alprazolam | 82 | 34 |
| Januvia | Sitagliptin Phosphate | 81 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 13 |
| Atenolol | Atenolol | 78 | 14 |
| Bupropion Xl | Bupropion Hcl | 77 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 77 | 12 |
| Latanoprost | Latanoprost | 76 | 16 |
| Enalapril Maleate | Enalapril Maleate | 72 | 19 |
| Linzess | Linaclotide | 72 | 19 |
| Spironolactone | Spironolactone | 70 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 12 |
| Benazepril Hcl | Benazepril Hcl | 68 | 12 |
| Tramadol Hcl | Tramadol Hcl | 65 | 23 |
| Ozempic | Semaglutide | 64 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 63 | 12 |
| Valsartan | Valsartan | 62 | 15 |
| Baclofen | Baclofen | 61 | suppressed |
| Myrbetriq | Mirabegron | 61 | 13 |
| Azithromycin | Azithromycin | 60 | 52 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 60 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 24 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 57 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 57 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 14 |
| Entresto | Sacubitril/Valsartan | 56 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 56 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | suppressed |
| Irbesartan | Irbesartan | 54 | 14 |
| Jardiance | Empagliflozin | 52 | 15 |
| Midodrine Hcl | Midodrine Hcl | 52 | suppressed |
| Synthroid | Levothyroxine Sodium | 51 | 18 |
| Levetiracetam | Levetiracetam | 48 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 47 | suppressed |
| Nifedipine Er | Nifedipine | 47 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 46 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 45 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 13 |
| Nystatin | Nystatin | 45 | 30 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 45 | 14 |
| Clonazepam | Clonazepam | 44 | 12 |
| Hydrocortisone | Hydrocortisone | 44 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 43 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 41 | 23 |
| Prednisone | Prednisone | 41 | 17 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Repatha Sureclick | Evolocumab | 39 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 33 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 31 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Telmisartan | Telmisartan | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 32 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 31 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 13 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Olanzapine | Olanzapine | 29 | suppressed |
| Anastrozole | Anastrozole | 28 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Lyrica | Pregabalin | 27 | suppressed |
| Folic Acid | Folic Acid | 26 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Klor-Con M20 | Potassium Chloride | 26 | 11 |
| Ofloxacin | Ofloxacin | 26 | 20 |
| Pitavastatin Calcium | Pitavastatin Calcium | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Febuxostat | Febuxostat | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | 19 |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Nyamyc | Nystatin | 25 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 16 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 23 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 23 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Alphagan P | Brimonidine Tartrate | 20 | suppressed |
| Amantadine | Amantadine Hcl | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 20 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 17 |
| Sucralfate | Sucralfate | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Clozapine | Clozapine | 18 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Multaq | Dronedarone Hcl | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 18 | suppressed |
| Lumigan | Bimatoprost | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Ursodiol | Ursodiol | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 14 | suppressed |
| Galantamine Er | Galantamine Hbr | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Nisoldipine | Nisoldipine | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Matzim La | Diltiazem Hcl | 12 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Carbidopa | Carbidopa | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Diazepam | Diazepam | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,291.24 · 64 records | ABBVIE INC. | ABRYSVO, COMIRNATY, CREON, Cologuard Collection Kit, DUPIXENT, GEMTESA, GLYCATE, JARDIANCE, Kerendia, LEQVIO, LINZESS, Ozempic, PERCEPT PC BRAINSENSE, PREVNAR 20, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REXULTI, Rybelsus, UBRELVY, VRAYLAR, Veozah, XIFAXAN | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error